AbbVie Inc.

ABBV · CIK 0001551152

15 fiscal years · 53 SEC filings · every number carries its receipt

Revenue (FY)

$61.16B8.6%

FY2025

Net income (FY)

$4.23B1.2%

FY2025

Free cash flow (FY)

$17.82B0.1%

FY2025

Diluted EPS (FY)

$2.361.3%

FY2025

The story, charted

The shape of the business

FY2011–FY2025 · hover any year for its receipt

Revenue & net incomeRevenueNet income

revenue 3.5× since FY2011 · net margin 8.9% → 6.9%

MarginsNet marginFCF margin

FY2025: net 6.9% · free cash flow 29.1% of revenue

Cash engineOperating cash flowFree cash flow

FY2025: $19.03B operating cash − $1.21B capex = $17.82B free cash flow

Returns on capitalReturn on equityReturn on assets

return on equity 102% (FY2014) → -129% (FY2025) · on assets 3.2%

The receipts

Financial statements

Annual Quarterly (as reported)

USD in millions except per-share and share counts. Every value links to the filing it came from — hover for the us-gaap tag, click for the 10-K/10-Q on sec.gov.

USD millions	Q1 2026	Q3 2025	Q2 2025	Q1 2025	Q3 2024	Q2 2024	Q1 2024	Q3 2023	Q2 2023	Q1 2023	Q3 2022	Q2 2022
Revenue	15,002	15,776	15,423	13,343	14,460	14,462	12,310	13,927	13,865	12,225	14,812	14,583
Net income	695	186	938	1,286	1,561	1,370	1,369	1,778	2,024	239	3,949	924
Diluted EPS	0.39	0.10	0.52	0.72	0.88	0.77	0.77	1.00	1.14	0.13	2.21	0.51
Diluted shares	1,774	1,772	1,771	1,772	1,772	1,771	1,773	1,771	1,771	1,776	1,776	1,776
Operating cash flow	3,829	—	—	1,635	—	—	4,040	—	—	4,193	—	—
Capital expenditures	265	—	—	235	—	—	193	—	—	175	—	—
Free cash flow	3,564	—	—	1,400	—	—	3,847	—	—	4,018	—	—
Cash & equivalents	9,391	5,629	6,467	5,175	7,257	13,130	18,067	13,287	8,759	6,711	11,832	8,521
Total assets	136,463	133,898	137,182	136,165	143,422	141,937	148,874	136,221	135,367	134,544	141,325	143,186
Shareholders' equity	(6,656)	(2,642)	(183)	1,420	6,032	6,778	8,007	12,094	12,866	13,274	15,994	14,653

Figures as reported in SEC filings, normalized by stonks with the tag mapping shown on hover; missing tags render as “—”, never as zero. Free cash flow is derived (operating cash flow − capex) with both parents recorded in its lineage. Quarterly view shows as-reported 10-Q periods; Q4 synthesis ships in Phase 1. See methodology.